RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia (CROSBI ID 298822)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Koschut, David ; Ray, Debleena ; Li, Zhenhua ; Giarin, Emanuela ; Groet, Jürgen ; Alić, Ivan ; Kham, Shirley Kow-Yin ; Chang, Wee Joo ; Ariffin, Hany ; Weinstock, David M. ; Yeoh, Allen Eng-Juh ; Basso, Giuseppe ; Nižetić, Dean
engleski
RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia
A population of more than six million people worldwide at high risk of Alzheimer’s disease (AD) are those with Down Syndrome (DS, caused by trisomy 21 (T21)), 70% of whom develop dementia during lifetime, caused by an extra copy of βamyloid-(Aβ)-precursor-protein gene. We report AD-like pathology in cerebral organoids grown in vitro from noninvasively sampled strands of hair from 71% of DS donors. The pathology consisted of extracellular diffuse and fibrillar Aβ deposits, hyperphosphorylated/pathologically conformed Tau, and premature neuronal loss. Presence/absence of AD-like pathology was donor-specific (reproducible between individual organoids/iPSC lines/experiments). Pathology could be triggered in pathology-negative T21 organoids by CRISPR/Cas9-mediated elimination of the third copy of chromosome 21 gene BACE2, but prevented by combined chemical β and γ- secretase inhibition. We found that T21 organoids secrete increased proportions of Aβ- preventing (Aβ1–19) and Aβ-degradation products (Aβ1–20 and Aβ1–34). We show these profiles mirror in cerebrospinal fluid of people with DS. We demonstrate that this protective mechanism is mediated by BACE2-trisomy and cross-inhibited by clinically trialled BACE1 inhibitors. Combined, our data prove the physiological role of BACE2 as a dose-sensitive AD-suppressor gene, potentially explaining the dementia delay in ~30% of people with DS. We also show that DS cerebral organoids could be explored as pre-morbid AD-risk population detector and a system for hypothesis-free drug screens as well as identification of natural suppressor genes for neurodegenerative diseases.
RAS, leukemia
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
40
2021.
746-762
objavljeno
0950-9232
1476-5594
https:// doi.org/10.1038/s41388-020-01567-7
Povezanost rada
Temeljne medicinske znanosti